hepatocellular carcinoma
Conditions
Interventions
The patients in the BCAA group received BCAA orally administration before tumor ablation therapy until 1 month after the therapy.
The patients in the diet group received diet therapy with defined dail
Sponsors
Yokohama City University Medical Center Gastroenterological Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Early-stage hepatocellular carcinoma(BCLC staging) 2)Compensated liver cirrhosis 3) Equal to or more than 20 years old.
Exclusion criteria
Exclusion criteria: Exclusion criteria are the presence of any one of the following: serum albumin <2.5mg dL, serum total bilirubin level <3mg/dL, hepatic encephalopathy of or above grade II, history of albumin infusion or receiving BCAA granules in the preceding 3 months, and bleeding varices.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short- to mid-term effects of liver function and nutrition status during the post ablative period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to tumor progression | — |
Countries
Japan
Contacts
Public ContactManabu Morimoto
Yokohama City University Medical Center Gastroenterological Center
Outcome results
None listed